Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
- DOI
- 10.1016/s0140-6736(16)31651-8
- Published
- 2016-12
- Container
- The Lancet
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-16-31651-8,
title = {Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study},
author = {Josef S Smolen and Gerd-Rüdiger Burmester and Bernard Combe and Jeffrey R Curtis and Stephen Hall and Boulos Haraoui and Ronald van Vollenhoven and Christopher Cioffi and Cécile Ecoffet and Leon Gervitz and Lucian Ionescu and Luke Peterson and Roy Fleischmann},
year = {2016},
journal = {The Lancet},
doi = {10.1016/s0140-6736(16)31651-8},
url = {https://doi.org/10.1016/s0140-6736(16)31651-8}
}RIS
TY - JOUR TI - Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study AU - Josef S Smolen AU - Gerd-Rüdiger Burmester AU - Bernard Combe AU - Jeffrey R Curtis AU - Stephen Hall AU - Boulos Haraoui AU - Ronald van Vollenhoven AU - Christopher Cioffi AU - Cécile Ecoffet AU - Leon Gervitz AU - Lucian Ionescu AU - Luke Peterson AU - Roy Fleischmann PY - 2016 JO - The Lancet DO - 10.1016/s0140-6736(16)31651-8 UR - https://doi.org/10.1016/s0140-6736(16)31651-8 ER -
APA
Smolen, J. S., Burmester, G., Combe, B., Curtis, J. R., Hall, S., Haraoui, B., Vollenhoven, R. V., Cioffi, C., Ecoffet, C., Gervitz, L., Ionescu, L., Peterson, L., & Fleischmann, R. (2016). Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. The Lancet. https://doi.org/10.1016/s0140-6736(16)31651-8
Source records
- crossref · retrieved 2026-11-10T14:20:53.113Z